# Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

> **NCT02326220** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Alirocumab

## Key facts

- **NCT ID:** NCT02326220
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-31
- **Primary completion:** 2016-01-31
- **Final completion:** 2016-04-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326220, "Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02326220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*